Maxwell, Jill A <br/><br/>
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Aug 2008 
 - 4859-68 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-4807  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Alkylating--pharmacology<br/>Base Pair Mismatch<br/>Brain Neoplasms--drug therapy<br/>DNA Mismatch Repair<br/>Dacarbazine--analogs & derivatives<br/>Drug Resistance, Neoplasm<br/>Female<br/>Glioblastoma--genetics<br/>Glioma--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>O(6)-Methylguanine-DNA Methyltransferase--genetics<br/>Temozolomide